| Ticker | Status | Jurisdiction | Filing Date | CP Start | CP End | CP Loss | Deadline |
|---|
| Ticker | Case Name | Status | CP Start | CP End | Deadline | Settlement Amt |
|---|
| Ticker | Name | Date | Analyst Firm | Up/Down | Target ($) | Rating Change | Rating Current |
|---|
CytomX Therapeutics, Inc. (NASDAQ:CTMX) shares are racing higher Wednesday. The company said it will report first-quarter results and provide an initial CX-904 Phase 1a dose escalation update on May 8 after the close of markets.
What To Know:
CytomX and Amgen, Inc. (NASDAQ:AMGN) are developing CX-904, a T-cell-engaging bispecific Probody candidate against the epidermal growth factor receptor (EGFR) on cancer cells and the CD3 receptor on T cells. The drug candidate is currently in a Phase 1 dose-escalation study in patients with advanced solid tumors.
CytomX shares are moving on heavy trading volume Wednesday and trading was halted on a circuit breaker. According to data from Benzinga Pro, more than 115 million shares have already been traded in the session, far exceeding the stock’s 100-day average of less than 919,000 shares.
Related News: What’s Going On With Rivian Automotive Stock?
Besides going to a brokerage platform to purchase a share – or fractional share – of stock, you can also gain access to shares either by buying an exchange traded fund (ETF) that holds the stock itself, or by allocating yourself to a strategy in your 401(k) that would seek to acquire shares in a mutual fund or other instrument.
For example, in CytomX Therapeutics' case, it is in the Health Care sector. An ETF will likely hold shares in many liquid and large companies that help track that sector, allowing an investor to gain exposure to the trends within that segment.
CTMX Price Action: According to Benzinga Pro, CytomX shares are up 169% at $4.39 at the time of publication Wednesday.
Image: PublicDomainPictures from Pixabay
